BRPI0913943A2 - método para determinar o prognóstico de um paciente que sofre de câncer e composição de agente indutor de atividade de chok(beta) - Google Patents

método para determinar o prognóstico de um paciente que sofre de câncer e composição de agente indutor de atividade de chok(beta)

Info

Publication number: BRPI0913943A2
Authority: BR; Brazil
Prior art keywords: beta; composition; cancer patient; inducing agent; determine prognosis
Prior art date: 2008-07-04

Application number

BRPI0913943A

Other languages

English (en)

Inventor

Ana Ramírez De Molina

David Gallego Ortega

Juan Carlos Lacal Sanjuán

Original Assignee

Translational Cancer Drugs Pharma S L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-04

Filing date

2009-07-06

Publication date

2015-10-20

2009-07-06 Application filed by Translational Cancer Drugs Pharma S L filed Critical Translational Cancer Drugs Pharma S L

2015-10-20 Publication of BRPI0913943A2 publication Critical patent/BRPI0913943A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01032—Choline kinase (2.7.1.32)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

BRPI0913943A 2008-07-04 2009-07-06 método para determinar o prognóstico de um paciente que sofre de câncer e composição de agente indutor de atividade de chok(beta) BRPI0913943A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200802007		2008-07-04
PCT/IB2009/052936 WO2010001369A2 (es)	2008-07-04	2009-07-06	Métodos para el tratamiento y diagnóstico del cáncer

Publications (1)

Publication Number	Publication Date
BRPI0913943A2 true BRPI0913943A2 (pt)	2015-10-20

Family

ID=41466389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0913943A BRPI0913943A2 (pt)	2008-07-04	2009-07-06	método para determinar o prognóstico de um paciente que sofre de câncer e composição de agente indutor de atividade de chok(beta)

Country Status (8)

Country	Link
US (2)	US20110250179A1 (pt)
EP (1)	EP2316970A2 (pt)
AU (1)	AU2009265121A1 (pt)
BR (1)	BRPI0913943A2 (pt)
CA (1)	CA2729857A1 (pt)
MX (1)	MX2011000147A (pt)
RU (1)	RU2509809C2 (pt)
WO (1)	WO2010001369A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2721174A1 (en) *	2011-06-20	2014-04-23	Traslational Cancer Drugs Pharma, S.L.	Method for predicting the clinical response to chemotherapy in a subject with cancer
EP2732049A1 (en) *	2011-07-14	2014-05-21	Traslational Cancer Drugs Pharma, S.L.	Method for predicting outcome of cancer in a subject
US11813338B2 (en)	2013-03-12	2023-11-14	The Trustees Of The University Of Pennsylvania	Diagnosing and treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RU2164419C2 (ru) *	1994-03-18	2001-03-27	Мириад Дженетикс, Инк.	Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5665702A (en)	1995-06-06	1997-09-09	Biomeasure Incorporated	Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en)	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
PT1053020E (pt)	1998-01-29	2004-06-30	Poly Med Inc	Microparticulas absorviveis
ES2237332B1 (es)	2004-01-14	2006-11-01	Consejo Sup. Investig. Cientificas	Derivados de piridinio y quinolinio.
PT1889920E (pt) *	2005-04-13	2010-04-14	Consejo Superior Investigacion	Método para a identificação in vitro de compostos para terapia do cancro
WO2007069090A2 (en)	2005-12-06	2007-06-21	Centre National De La Recherche Scientifique	Cell penetrating peptides for intracellular delivery of molecules
US20080318234A1 (en) *	2007-04-16	2008-12-25	Xinhao Wang	Compositions and methods for diagnosing and treating cancer

2009
- 2009-07-06 MX MX2011000147A patent/MX2011000147A/es active IP Right Grant
- 2009-07-06 EP EP09764040A patent/EP2316970A2/en not_active Withdrawn
- 2009-07-06 CA CA2729857A patent/CA2729857A1/en not_active Abandoned
- 2009-07-06 BR BRPI0913943A patent/BRPI0913943A2/pt not_active IP Right Cessation
- 2009-07-06 AU AU2009265121A patent/AU2009265121A1/en not_active Abandoned
- 2009-07-06 RU RU2011142986/10A patent/RU2509809C2/ru not_active IP Right Cessation
- 2009-07-06 WO PCT/IB2009/052936 patent/WO2010001369A2/es active Application Filing
- 2009-07-06 US US13/001,637 patent/US20110250179A1/en not_active Abandoned
2014
- 2014-10-08 US US14/509,349 patent/US20150098927A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150098927A1 (en)	2015-04-09
MX2011000147A (es)	2011-05-24
RU2011142986A (ru)	2013-04-27
EP2316970A2 (en)	2011-05-04
US20110250179A1 (en)	2011-10-13
CA2729857A1 (en)	2010-01-07
RU2509809C2 (ru)	2014-03-20
AU2009265121A1 (en)	2010-01-07
WO2010001369A3 (es)	2010-04-15
WO2010001369A2 (es)	2010-01-07

Similar Documents

Publication	Publication Date	Title
BR112012008854A2 (pt)	2015-09-22	combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0811589A2 (pt)	2014-10-29	Composição farmacêutica e método para tratar câncer
BRPI0906576A2 (pt)	2015-07-07	Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BR112013009142A2 (pt)	2016-07-26	"composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
DE602007004699D1 (de)	2010-03-25	Aryl(thio)ether-Aryl-Polysiloxan-Zusammensetzung sowie Herstellungs- und Verwendungsverfahren dafür
BRPI0919238A2 (pt)	2019-09-24	métodos e composições para o tratamento de câncer
BR112012001713A2 (pt)	2016-04-12	composições para tratamento bucal que compreendem íons estanoso e potássio
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
BRPI0915284A2 (pt)	2015-08-04	Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI1008566A2 (pt)	2017-06-06	métodos e composições para o diagnóstico e tratamento de câncer
BRPI0808410A2 (pt)	2015-06-23	Métodos e composições para normalizar secreções da glândula meibomiana
CO6210786A2 (es)	2010-10-20	Implemento de cuidado oral que alberga un agente de cuidado oral
BR112013002167A2 (pt)	2016-05-31	anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
BR112014019750A8 (pt)	2018-01-16	composto, composlção farmacêutlca, método para aumentar a lnclusão de éxon 7 de smn2 em mrna, método para aumentar a quantidade de proteína smn e método para tratar sma em um indivíduo humano em necessidade
ZA201008030B (en)	2011-07-27	Method and composition for skin inflammation and discoloration
BRPI0822220A2 (pt)	2015-06-23	Composições contendo enzima e agente de matiz para tecidos
BRPI0908854A2 (pt)	2019-09-24	composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0818073A2 (pt)	2015-03-31	Composição de fluido de tratamento de poço e métodos de uso que incluem uma formulação de percarbonato de liberação retardada
BRPI1008564A2 (pt)	2018-02-27	métodos e composições para o dignóstico e tratamento de câncer
BRPI1007972A2 (pt)	2016-09-13	composições de combinação e métodos para o tratamento de câncer
BRPI0911112A2 (pt)	2015-10-06	composições e métodos para o tratamento do câncer de mama
BRPI0910760A2 (pt)	2018-03-20	método para remineralizar tecido, agente remineralizador, e, kit
BRPI0822349A2 (pt)	2019-09-24	composições e métodos para tratar doenças lisossômicas

Legal Events

Date	Code	Title	Description
2016-08-30	B25G	Requested change of headquarter approved	Owner name: TRANSLATIONAL CANCER DRUGS PHARMA, S.L. (ES)
2016-09-13	B08F	Application fees: dismissal - article 86 of industrial property law	Free format text: REFERENTE A 7A ANUIDADE.
2017-01-10	B08K	Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.